In vitro effects of some flavonoids and phenolic acids on human pyruvate kinase isoenzyme M2

References

• Goel A, Mathupala SP, Pedersen PL. Glucose metabolism in cancer: evidence that demethylation events play a role in activating type II hexokinase gene expression. J Biol Chem 2003;278:15333–40
   PubMed Web of Science ®Google Scholar
• Locasale JW, Cantley LC. Altered metabolism in cancer. BMC Biol 2010;8:88
   PubMed Web of Science ®Google Scholar
• Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013;4:e532
   PubMed Web of Science ®Google Scholar
• Harris I, McCracken S, Mak TW. PKM2: a gatekeeper between growth and survival. Cell Res 2012;22:447–9
   PubMed Web of Science ®Google Scholar
• Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol 2011;43:969–80
   PubMed Web of Science ®Google Scholar
• Spoden GA, Rostek U, Lechner S, et al. Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply. Exp Cell Res 2009;315:2765–74
   PubMed Web of Science ®Google Scholar
• Mazurek S, Hugo F, Zwerschke W. PKM2 (pyruvate kinase isoenzyme type M2). Atlas Genet Cytogenet Oncol Haematol 2009;13:276–81
   Google Scholar
• Chahar MK, Sharma N, Dobhal MP, Joshi YC. Flavonoids: a versatile source of anticancer drugs. Pharmacogn Rev 2011;5:1–12
   PubMedGoogle Scholar
• Ravishankar D, Rajora AK, Greco F, Osborn HMI. Flavonoids as prospective compounds for anti-cancer therapy. Int J Biochem Cell Biol 2013;45:2821–31
   PubMed Web of Science ®Google Scholar
• Ganapathy-Kanniappan S, Geschwind JFH. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer 2013;12:152
   PubMed Web of Science ®Google Scholar
• Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008;452:230–3
   PubMed Web of Science ®Google Scholar
• Munoz-Pinedo C, El Mjiyad N, Ricci JE. Cancer metabolism: current perspectives and future directions. Cell Death Dis 2012;3:e248
   PubMed Web of Science ®Google Scholar
• Wu S, Le H. Dual roles of PKM2 in cancer metabolism. Acta Biochim Biophys Sinica 2013;45:27–35
   PubMed Web of Science ®Google Scholar
• Orlikova B, Legrand N, Panning J, et al. Anti-inflammatory and anticancer drugs from nature. Cancer Treat Res 2014;159:123–43
   PubMedGoogle Scholar
• Khazir J, Mir BA, Pilcher L, Riley DL. Role of plants in anticancer drug discovery. Phytochem Lett 2014;7:173–81
   Web of Science ®Google Scholar
• Mushtaq M, Wani SM. Polyphenols and human health – a review. Int J Pharma BioSci 2013;4:B338–60
   Google Scholar
• Kumar S, Narwal S, Kumar V, Prakash O. α-Glucosidase inhibitors from plants: a natural approach to treat diabetes. Pharmacogn Rev 2011;5:19–29
   PubMedGoogle Scholar
• Bansal T, Jaggi M, Khar R, Talegaonkar S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. Int J Pharm Pharm Sci 2009;12:46–78
   Web of Science ®Google Scholar
• Nagao A, Seki M, Kobayashi H. Inhibition of xanthine oxidase by flavonoids. Biosci Biotechnol Biochem 1999;63:1787–90
   PubMed Web of Science ®Google Scholar
• Ekinci D, Karagoz L, Ekinci D, et al. Carbonic anhydrase inhibitors: in vitro inhibition of α isoforms (hCA I, hCA II, bCA III, hCA IV) by flavonoids. J Enzyme Inhib Med Chem 2014;28:283–8
   Web of Science ®Google Scholar
• Balaydin HT, Durdaği S, Ekinci D, et al. Inhibition of human carbonic anhydrase isozymes I, II and VI with a series of bisphenol, methoxy and bromophenol compounds. J Enzyme Inhib Med Chem 2012;27:467–75
   PubMed Web of Science ®Google Scholar
• Koz Ö, Ekinci D, Perrone A, et al. Analysis of saponins and phenolic compounds as inhibitors of α-carbonic anhydrase isoenzymes. J Enzyme Inhib Med Chem 2014;28:412–17
   Web of Science ®Google Scholar
• Ekinci D, Cavdar H, Durdagi S, et al. Structure-activity relationships for the interaction of 5,10-dihydroindeno[1,2-b]indole derivatives with human and bovine carbonic anhydrase isoforms I, II, III, IV and VI. Eur J Med Chem 2012;49:68–73
   PubMed Web of Science ®Google Scholar
• Durdagi S, Entürk M, Ekinci D, et al. Kinetic and docking studies of phenol-based inhibitors of carbonic anhydrase isoforms I, II, IX and XII evidence a new binding mode within the enzyme active site. Bioorg Med Chem 2011;19:1381–9
   PubMed Web of Science ®Google Scholar
• Sun F, Zheng XY, Ye J, et al. Potential anticancer activity of myricetin in human T24 bladder cancer cells both in vitro and in vivo. Nutr Cancer 2012;64:599–606
   PubMed Web of Science ®Google Scholar
• Adhami VM, Syed DN, Khan N, Mukhtar H. Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management. Biochem Pharmacol 2012;84:1277–81
   PubMed Web of Science ®Google Scholar
• Damia G, Garattini S. The pharmacological point of view of resistance to therapy in tumors. Cancer Treat Rev 2014;40:909–16
   PubMed Web of Science ®Google Scholar
• Sullivan EJ, Kurtoglu M, Brenneman R, et al. Targeting cisplatin-resistant human tumor cells with metabolic inhibitors. Cancer Chemother Pharmacol 2014;73:417–27
   PubMed Web of Science ®Google Scholar
• Lisanti MP, Martinez-Outschoorn UE, Sotgia F. Oncogenes induce the cancer-associated fibroblast phenotype: metabolic symbiosis and “fibroblast addiction” are new therapeutic targets for drug discovery. Cell Cycle 2013;12:2723–32
   PubMed Web of Science ®Google Scholar